1. Phorboxazoles A and B: potent cytostatic macrolides from marine sponge Phorbas species
2. GI50is defined as the concentration at which cell growth is inhibited by 50%. (a) Suffness, M.; Newman, D. J.; Snader, K.Discovery and Development of AntineoplasticAgents from Natural Sources; Scheuer, P. J., Ed.; Springer-Verlag: Berlin, 1989; Vol. 3, p 175. (b) Boyd, M. R.; Paull, K. D.; Rubinstein, L. R. InAntitumor Drug Discovery andDevelopment; Valeriote, F., Corbett, T., Baker, L., Eds., Kluwer Academic: Amsterdam, 1991; pp 11−34. (c) Boyd, M. R.; Paull, K. D.Drug Dev. Res. 1995, 34, 91−109. Phorboxazole A also showed selectivity against leukemia CCRF-CBM (GI502.45 × 10-10M), prostate cancer PC-3 (3.54 × 10-10M) and breast cancer MCF7 cell lines (5.62 × 10-10M), although high activity was seen across the entire panel of cell lines (mean GI501.58 × 10-9M). Compounds1and2had essentially the same activity profiles. We are grateful to Drs. Jill Johnson and Anthony B. Mauger, National Cancer Institute, for these data.The phorboxazoles A and B have been selected by the NCI for in vivo antitumor trials.
3. High-field FT NMR application of Mosher's method. The absolute configurations of marine terpenoids